Neurowave Medical Technologies is committed to being the leader in the development of non-invasive nerve stimulation medical devices for various clinical indications and acute and chronic disease states. 
NMT’s goal is to develop innovative non-invasive medical devices that can treat serious clinical conditions by replacing current pharmaceutical treatments for those same diseases.
NMT’s goal is to develop innovative non-invasive medical devices that can treat serious clinical conditions by replacing current pharmaceutical treatments for those same diseases.
The first clinical products to be FDA approved using NMT’s patented Nerve Stimulation Technology are the ReliefBand Medical Device (RBMD™) family of products. The RBMD is a unique non-drug, non-invasive, medical device for the treatment of Emesis (nausea and vomiting) in multiple clinical indications. The RBMD is the perfect fusion of ease of use, efficacy, and safety of a medical device with the proven therapeutic benefit of a leading pharmaceutical product for the same clinical conditions.
The RBMD™ has FDA approvals for the following clinical indications:
- Chemotherapy Induced Nausea & Vomiting (CINV)
- Pregnancy Induced Nausea & Vomiting (PINV) or more commonly known as- morning sickness
- As an adjunct to anti-emetics for Post-Operative Nausea & Vomiting (PONV)
- Motion Sickness Induced Nausea & Vomiting (MSNV)
NMT is continuously researching new clinical indications, designs, and markets for its propriety pulse generation platform based on its patented Nerve Stimulation Technology.
